Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Aldeyra Therapeutics, Inc. (ALDX)

1.4700 -0.0100 (-0.68%)
As of 12:13:50 PM EDT. Market Open.
Trade ALDX on Coinbase
Chart Range Bar
Loading chart for ALDX
  • Previous Close 1.4800
  • Open 1.4700
  • Bid 1.0600 x 200
  • Ask 1.8900 x 200
  • Day's Range 1.4600 - 1.4800
  • 52 Week Range 1.0700 - 5.9300
  • Volume 137,964
  • Avg. Volume 1,268,106
  • Market Cap (intraday) 88.68M
  • Beta (5Y Monthly) 1.19
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3800
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.60

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

www.aldeyra.com

6

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ALDX
71.62%
S&P 500 (^GSPC)
12.79%

1-Year Return

ALDX
73.42%
S&P 500 (^GSPC)
18.75%

3-Year Return

ALDX
80.58%
S&P 500 (^GSPC)
70.99%

5-Year Return

ALDX
84.06%
S&P 500 (^GSPC)
70.24%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -5.45M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

2.00
6.60 Average
1.4700 Current
13.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/18/2026
Analyst HC Wainwright & Co.
Rating Action Downgrade
Rating Neutral
Price Action Lowers
Price Target 10 -> 2

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    89.89M

  • Enterprise Value

    44.94M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.37

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -22.70%

  • Return on Equity (ttm)

    -49.48%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -23.05M

  • Diluted EPS (ttm)

    -0.3800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    45.09M

  • Total Debt/Equity (mrq)

    0.38%

  • Levered Free Cash Flow (ttm)

    -15.62M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.4700 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: